MA02.07 T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm+ NSCLC: Interim Analysis of a Phase II Trial M. Jebbink,A.J. de Langen,Kim Monkhorst,Mirjam C. Boelens,D. Van Den Broek,Vincent van der Noort,C.J. de Gooijer,A. J. van der Wekken,Lizza E.L. Hendriks,Sayed M.S. Hashemi, Marthe S. Paats,A-M.C. Dingemans,Egbert F. SmitJournal of Thoracic Oncology（2021）引用 4|浏览4暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
